Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.
